Shots:

• The P-III CHOICE-01 trial evaluates toripalimab + CT vs CT alone in 465 patients in a ratio (2:1) with advanced sq./nonsq. NSCLC without driver mutations
• The interim analysis met its 1EPs i.e.- improvement in PFS- superior ORR & DoR- OS data are still maturing. The safety profile was consistent with PD-1 inhibitor while final PFS & additional interim OS analyses are expected in later 2021
• The companies plan to discuss with US FDA for submission of toripalimab’s BLA to treat NSCLC. The therapy has received FTD for mucosal melanoma- ODD for NPC- mucosal melanoma & soft tissue sarcoma- BTD for combination therapy as 1L treatment & for monothx. as 2L treatment of recurrent or metastatic NPC

  | Ref: Globe Newswire | Image: Coherus